{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Immutep Limited"},"Symbol":{"label":"Symbol","value":"IMMP"},"Address":{"label":"Address","value":"264 GEORGE STREET,LEVEL 33, AUSTRALIA SQUARE, SYDNEY, 2000, Australia"},"Phone":{"label":"Phone","value":"+61 283157003"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Australia and South Pacific"},"CompanyDescription":{"label":"Company Description","value":"Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's unique ability to stimulate or suppress the immune response. Immutep's lead clinical candidate, eftilagimod alpha ('efti'), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer."},"CompanyUrl":{"label":"Company Url","value":"https://www.immutep.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Deanne Miller","title":"COO, Secretary & General Counsel"},{"name":"Florian D. Vogl","title":"Chief Medical Officer"},{"name":"Frédéric Triebel","title":"Executive Director & Chief Scientific Officer"},{"name":"Marc Voigt","title":"Chief Executive Officer & Executive Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}